These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36476010)

  • 1. Clinically meaningful change: evaluation of the Rasch-built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) and the ALSFRS-R.
    Fournier CN; James V; Glass JD
    Amyotroph Lateral Scler Frontotemporal Degener; 2023 May; 24(3-4):311-316. PubMed ID: 36476010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and Validation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS).
    Fournier CN; Bedlack R; Quinn C; Russell J; Beckwith D; Kaminski KH; Tyor W; Hertzberg V; James V; Polak M; Glass JD
    JAMA Neurol; 2020 Apr; 77(4):480-488. PubMed ID: 31886839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal comparison of the self-entry Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-RSE) and Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) as outcome measures in people with amyotrophic lateral sclerosis.
    Johnson SA; Burke KM; Scheier ZA; Keegan MA; Clark AP; Chan J; Fournier CN; Berry JD
    Muscle Nerve; 2022 Oct; 66(4):495-502. PubMed ID: 35904151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chinese validation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale.
    Sun C; Fournier CN; Ye S; Zhang N; Ma Y; Fan D
    Eur J Neurol; 2021 Jun; 28(6):1876-1883. PubMed ID: 33686758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do we really need to calculate a minimal important difference for ALSFRS-R?: A letter in response to 'Clinically meaningful change: evaluation of the Rasch-built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) and the ALSFRS-R' published in Vol. 24(3-4), pp. 311-316.
    Vázquez-Costa JF
    Amyotroph Lateral Scler Frontotemporal Degener; 2024 Feb; 25(1-2):214-215. PubMed ID: 37647208
    [No Abstract]   [Full Text] [Related]  

  • 6. Validation of the Italian version of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) administered to patients and their caregivers.
    Manera U; Solero L; Fournier CN; Canosa A; Vasta R; Bombaci A; Grassano M; Palumbo F; Torrieri MC; Salamone P; Casale F; Fuda G; Moglia C; Calvo A; Chiò A
    Amyotroph Lateral Scler Frontotemporal Degener; 2022 Aug; 23(5-6):424-429. PubMed ID: 34894916
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical significance in the change of decline in ALSFRS-R.
    Castrillo-Viguera C; Grasso DL; Simpson E; Shefner J; Cudkowicz ME
    Amyotroph Lateral Scler; 2010; 11(1-2):178-80. PubMed ID: 19634063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving the measurement properties of the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R): deriving a valid measurement total for the calculation of change.
    Young CA; Chaouch A; Mcdermott CJ; Al-Chalabi A; Chhetri SK; Talbot K; Malaspina A; Mills R; Tennant A
    Amyotroph Lateral Scler Frontotemporal Degener; 2024 May; 25(3-4):400-409. PubMed ID: 38426231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Italian version of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS): validation and longitudinal performance.
    Fortuna A; Sabbatini D; Frigo A; Bello L; Calvi F; Blasi L; Gianferrari G; Martinelli I; Minicuci G; Pegoraro E; Mandrioli J; Sorarù G
    J Neurol; 2023 Mar; 270(3):1452-1456. PubMed ID: 36383259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Remote digital assessment of amyotrophic lateral sclerosis functional rating scale - a multicenter observational study.
    Meyer T; Spittel S; Grehl T; Weyen U; Steinbach R; Kettemann D; Petri S; Weydt P; Günther R; Baum P; Schlapakow E; Koch JC; Boentert M; Wolf J; Grosskreutz J; Rödiger A; Ilse B; Metelmann M; Norden J; Koc RY; Körtvélyessy P; Riitano A; Walter B; Hildebrandt B; Schaudinn F; Münch C; Maier A
    Amyotroph Lateral Scler Frontotemporal Degener; 2023 May; 24(3-4):175-184. PubMed ID: 35912984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the Measurement Properties of the Self-Administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R): A Rasch Analysis.
    Mehdipour A; Teshler L; Dal Bello-Haas V; Richardson J; Beauchamp M; Turnbull J; Chum M; Johnston W; O'Connell C; Luth W; Kuspinar A
    Phys Ther; 2023 Nov; 103(11):. PubMed ID: 37581600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient reported outcomes in ALS: characteristics of the self-entry ALS Functional Rating Scale-revised and the Activities-specific Balance Confidence Scale.
    Chew S; Burke KM; Collins E; Church R; Paganoni S; Nicholson K; Babu S; Scalia JB; De Marchi F; Ellrodt AL; Moura LMVR; Chan J; Berry JD
    Amyotroph Lateral Scler Frontotemporal Degener; 2021 Nov; 22(7-8):467-477. PubMed ID: 33771057
    [No Abstract]   [Full Text] [Related]  

  • 13. Plateaus and reversals evaluated by different methods in patients with limb-onset amyotrophic lateral sclerosis.
    Hu N; Shen D; Yang X; Cui L; Liu M
    J Clin Neurosci; 2022 Mar; 97():93-98. PubMed ID: 35074582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The frequency of ALSFRS-R reversals and plateaus in patients with limb-onset amyotrophic lateral sclerosis: a cohort study.
    Hu N; Shen D; Yang X; Cui L; Liu M
    Acta Neurol Belg; 2022 Dec; 122(6):1567-1573. PubMed ID: 35034333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
    ;
    Lancet Neurol; 2017 Jul; 16(7):505-512. PubMed ID: 28522181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The MITOS system predicts long-term survival in amyotrophic lateral sclerosis.
    Tramacere I; Dalla Bella E; Chiò A; Mora G; Filippini G; Lauria G;
    J Neurol Neurosurg Psychiatry; 2015 Nov; 86(11):1180-5. PubMed ID: 25886781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Qualitative measures that assess functional disability and quality of life in ALS.
    Hartmaier SL; Rhodes T; Cook SF; Schlusser C; Chen C; Han S; Zach N; Murthy V; Davé S
    Health Qual Life Outcomes; 2022 Jan; 20(1):12. PubMed ID: 35062955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell-based therapies for amyotrophic lateral sclerosis/motor neuron disease.
    Abdul Wahid SF; Law ZK; Ismail NA; Lai NM
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011742. PubMed ID: 31853962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations between the ALSFRS-R score and urate levels during 12 months of edaravone treatment for amyotrophic lateral sclerosis: Post hoc analysis of ALSFRS-R scores in clinical studies MCI186-16, MCI186-17, and MCI186-19.
    Takahashi F; Kano O; Nagano Y; Yoneoka T; Nelson S; Ushirogawa Y
    Muscle Nerve; 2022 Nov; 66(5):593-602. PubMed ID: 36053970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using the ALSFRS-R in multicentre clinical trials for amyotrophic lateral sclerosis: potential limitations in current standard operating procedures.
    Bakers JNE; de Jongh AD; Bunte TM; Kendall L; Han SS; Epstein N; Lavrov A; Beelen A; Visser-Meily JMA; van den Berg LH; van Eijk RPA
    Amyotroph Lateral Scler Frontotemporal Degener; 2022 Nov; 23(7-8):500-507. PubMed ID: 34949141
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.